Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ: ASND )

131.57 -2.47 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 462,422
Open 135.30
Bid (Size) 110.00 (2)
Ask (Size) 160.00 (12)
Prev. Close 134.04
Today's Range 130.97 - 137.54
52wk Range 111.09 - 161.00
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
Via Benzinga

Performance

YTD
-4.66%
-4.66%
1 Month
-3.68%
-3.68%
3 Month
+3.35%
+3.35%
6 Month
-6.56%
-6.56%
1 Year
-1.45%
-1.45%

More News

Read More
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
Via MarketBeat
(ASND) - Analyzing Ascendis Pharma's Short Interest
Via Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Via Benzinga
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
Via Benzinga
3 Oversold Stocks with Big RSI Rebound Potential
Via MarketBeat
Topics Economy
Exposures Interest Rates
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Via Benzinga
Exposures Product Safety
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
Via The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.